| Literature DB >> 12620421 |
Maria Letizia Barreca1, Alba Chimirri, Erik De Clercq, Laura De Luca, Anna-Maria Monforte, Pietro Monforte, Angela Rao, Maria Zappalà.
Abstract
This paper reports our work in the field of nonnucleoside RT inhibitors (NNRTIs). On the basis of extensive studies on 1H,3H-thiazolo[3,4-a]benzimidazole derivatives (TBZs) followed by structure-activity relationship (SAR) considerations and molecular modeling, the design and synthesis of a series of 2,3-diaryl-1,3-thiazolidin-4-ones have been performed. Some derivatives proved to be highly effective in inhibiting human immunodeficiency virus type-1 (HIV-1) replication at nanomolar concentrations with minimal toxicity, acting as reverse transcriptase (RT) inhibitors. Computational studies were used in order to probe the binding of our ligands to HIV-1-RT. Copyright 2003 Editions scienctifiques et médicales Elsevier SASEntities:
Mesh:
Substances:
Year: 2003 PMID: 12620421 DOI: 10.1016/S0014-827X(03)00024-7
Source DB: PubMed Journal: Farmaco ISSN: 0014-827X